A comprehensive onconephrology review links modern anti-cancer therapies to rising nephrotoxicity — including proteinuria alongside AKI, CKD, hypertension, and electrolyte disorders — that can force dose reductions or discontinuation. The review outlines mechanisms and practical approaches to evaluate kidney function and mitigate risk during treatment for malignant neoplasm.

Why It Matters To Your Practice

• Proteinuria on therapy may be an early signal of drug-related glomerular injury and a predictor of downstream CKD risk.

• Renal toxicity can directly disrupt cancer care (delays, dose changes, discontinuation), so timely triage and monitoring protect both kidney and oncologic outcomes.

• NPs/PAs often catch the first abnormal urinalysis or rising creatinine — and can trigger the right confirmatory testing and referrals.

Clinical Benefits

• Standardized surveillance (baseline + interval UA/UPCR and BMP) helps detect nephrotoxicity earlier, before symptoms develop.

• Early co-management with oncology/nephrology can preserve eligibility for effective therapy by addressing reversible contributors (volume status, concomitant nephrotoxins, uncontrolled BP).

• Clear thresholds for escalation reduce unnecessary treatment holds while prioritizing patient safety.

Managing Risks

• Confirm true proteinuria: repeat urinalysis and quantify with urine protein-to-creatinine ratio (or albumin-to-creatinine ratio when appropriate); assess for hematuria/casts.

• Risk-stratify quickly: check creatinine/eGFR trend, blood pressure, edema, and review the cancer agent class (targeted therapies and immunotherapies can have distinct renal injury patterns).

• Rule out common amplifiers: dehydration, NSAIDs, PPIs, ACEi/ARB/diuretics changes, infection, uncontrolled diabetes, and recent contrast exposure.

• Escalate when indicated: nephrology referral for nephrotic-range proteinuria, concurrent AKI, active urine sediment, rapidly rising protein levels, or systemic features suggesting immune-mediated disease.

• Coordinate medication decisions: align with oncology on whether to continue, hold, dose-reduce, or switch therapy; document severity and trends to support shared decision-making.

The Bottom Line

• Proteinuria during cancer therapy is common enough to warrant proactive screening and can be the first sign of meaningful kidney injury.

• Quantify, trend, and look for red flags (AKI, active sediment, nephrotic features) — then coordinate early with oncology and nephrology to avoid preventable treatment interruptions.